USA - NASDAQ:GEMI - US36866J1051 - Common Stock
| Date | Firm | Action | Rating | 
|---|---|---|---|
| 2025-10-24 | Truist Securities | Maintains | Buy -> Buy | 
| 2025-10-07 | Cantor Fitzgerald | Initiate | Overweight | 
| 2025-10-07 | Needham | Initiate | Buy | 
| 2025-10-07 | Rosenblatt | Initiate | Buy | 
| 2025-10-07 | Barclays | Initiate | Equal-Weight | 
| 2025-10-07 | Evercore ISI Group | Initiate | Outperform | 
| 2025-10-07 | Truist Securities | Initiate | Buy | 
| 2025-10-07 | Morgan Stanley | Initiate | Equal-Weight | 
| 2025-10-07 | Citigroup | Initiate | Neutral | 
null analysts have analysed GEMI and the average price target is 30.7 USD. This implies a price increase of 72.58% is expected in the next year compared to the current price of 17.79.